MARVEL-TTAS

Multicenter Apixaban theRapy for VEnous thromboemboLism and evaluation by Total Thrombus-formation Analysis System study - MARVEL-TTAS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs071180059

Enrollment

120

Registered

2019-03-19

Start date

2019-09-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep vein thrombosis

Interventions

Administer 20mg/day apixaban (20mg/day) for 7days and 10mg/day apixaban following days as antithrombotic therapy for patients with deep vein thrombosis.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: New onset case of venous thromboembolism and deep vein thrombosis, who requires permanent antithrombotic therapy

Exclusion criteria

Exclusion criteria: 1. contraindication of apixaban usage 2. Patients who are already taking antithrombotic or thrombolytic therapies 3. Patients who are judged as an inappropriate case to enroll

Design outcomes

Primary

Measure	Time frame
Fluctuation of AR10-AU C30 value with or without bleeding events	—

Secondary

Measure	Time frame
1) Fluctuation of AR10-AUC30 value in the case of venous thromboembolism 2) Fluctuation of AR10-AUC30 value after the remission venous thromboembolism 3) All death 4) Other adverse events	—

Contacts

Public ContactYuichiro Arima

IRCMS

arimay@kumamoto-u.ac.jp+81-96-373-6874

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026